We live in a time when tackling disease is urgent and in high demand. Just as medicine and technology evolve to unprecedented levels of sophistication, so do new, complex diseases that affect growing populations around the world. We need solutions that respond to our ever-changing lives, which means our solutions must be able to evolve. Fortunately, new tools and perspectives are sparking innovation and vital collaboration.
In the past few years, advances in biomedical research have opened pathways that allow us to edit genetic material, use stem cells to treat disease, and destroy cancer cells with novel immunotherapies. These advances (and many more) have vastly improved our capacity to tackle tough challenges in medicine.
Also, developments in technology have allowed researchers to put patients and public health at the center of many studies, resulting in large data sets that give us the ability to investigate new hypotheses for therapies and cures.
Yet novel interventions aren’t available to all patients, and we are experiencing information overload. How do we adjust to all of these changes in healthcare? How do we ensure new tools benefit everyone?
At the Helmsley Charitable Trust, we believe that a collaborative environment is crucial for sharing data, ideas, and solutions. Having supported hundreds of millions of dollars in health and medical research, we’ve learned and practiced some important lessons, including:
Foster an environment of trust. Last but not least, participants should feel comfortable sharing ideas, communicating, and giving constructive criticism.
Data-driven innovation allows us to understand difficult diseases and develop better treatments than ever before. But these advances can’t happen in isolation. Collaboration is essential as data multiply and research funding becomes scarce.
Fortunately, innovators today have created platforms for collecting and analyzing large data sets. When data are actionable, if the results of large analyses provide clues for interventions, we can tangibly improve the lives of people with diseases.
With the rise of social media and the ability to easily share information, the patient’s voice has become more prominent than ever before. Patients’ opinions are essential in the development of interventions. We must create a framework where all patients can be heard and contribute to our efforts.
At Helmsley, we are working on a collaborative health policy initiative that uses the patient’s voice to improve access to therapies and technologies for type 1 diabetes (T1D). This partnership between Helmsley, JDRF, and T1D Exchange paves a path toward greater adoption of effective therapies that could transform diabetes care. By bringing in the patient’s and clinician’s perspectives, along with data, we hope to identify roadblocks preventing all people with T1D from accessing technologies that can ease the burden of their disease.
Our lifestyles are radically evolving — from how we eat, exercise, and work, to how we treat disease. We are moving toward a world where collaboration connects all disciplines and stakeholders, in the hope of creating better, longer, healthier lives.
Originally featured in the Milken Institute “Power of Ideas” publication.
Gina Agiostratidou is the Director of the Type 1 Diabetes Program at The Leona M. and Harry B. Helmsley Charitable Trust.
Calling all HuffPost superfans!
Sign up for membership to become a founding member and help shape HuffPost’s next chapter